<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070718</url>
  </required_header>
  <id_info>
    <org_study_id>43952-B</org_study_id>
    <secondary_id>GYN-01-2012</secondary_id>
    <nct_id>NCT02070718</nct_id>
  </id_info>
  <brief_title>Effects of a Kappa Agonist on Hot Flashes in Menopausal Women</brief_title>
  <official_title>Effects of a Kappa Agonist on Hot Flashes in Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies suggest that kappa agonists (KA) and peripherally restricted kappa agonists (PRKAs)
      may affect thermoregulation. This pilot study has the aim to establish proof of concept
      regarding efficacy of an oral kappa agonist (KA) for the treatment of menopausal hot flashes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/
      Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.

      To gather data in support of a future proposal to study the safety and efficacy of a PRKA, a
      type of KA, for amelioration of menopausal hot flashes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot Flashes</measure>
    <time_frame>1-4 weeks</time_frame>
    <description>Objectively measured hot flash frequency by changes in skin conductance over 8 hours on 3 separate study visits 3-14 days apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjectively measured hot flashes</measure>
    <time_frame>1-4 weeks</time_frame>
    <description>Self-reported diary documentation of time and occurence of hot flashes and intensity of hot flashes over 8 hours on 3 separate study visits 3-14 days apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Leutinizing Hormone</measure>
    <time_frame>1-4 weeks</time_frame>
    <description>Serum collected at each visit baseline (before administration of treatment) and at 20-minute intervals over 8 hours on 3 separate study visits 3-14 days apart.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Follicle Stimulating Hormone</measure>
    <time_frame>Baseline only</time_frame>
    <description>Baseline (1st visit) single time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Estradiol</measure>
    <time_frame>Baseline only</time_frame>
    <description>Baseline (1st visit) single time point only.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Treatment of Menopausal Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cornstarch, National Formulary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Kappa Agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentazocine/Naloxone 50/0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Half Dose Kappa Agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentazocine/Naloxone 25/0.25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Dose Kappa Agonist</intervention_name>
    <arm_group_label>Standard Dose Kappa Agonist</arm_group_label>
    <other_name>Pentazocine/Naloxone 50/0.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half Dose Kappa Agonist</intervention_name>
    <arm_group_label>Half Dose Kappa Agonist</arm_group_label>
    <other_name>Pentazocine/Naloxone 25/0.25 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy women 45-60 years of age; 12 months amenorrhea

          2. Documentation of &gt; 8 moderate to severe, daily hot flashes during one week of baseline
             monitoring using daily diaries

          3. Availability of a family member or friend to drive participant home following clinic
             visits

        Exclusion Criteria:

          1. Use of hormonal prescription medication or supplements for vasomotor symptoms (VMS)

          2. Use of narcotics

          3. Use of SSRI (selective serotonin reuptake inhibitor)/SNRI (serotonin-norepinephrine
             reuptake inhibitors), gabapentin, MAOI (monoamine oxidase inhibitor), anti-epileptics,
             sedatives

          4. History of polycystic ovarian syndrome or hirsutism

          5. Current history of depression

          6. Any chronic or acute medical illnesses including renal, hepatic, pulmonary diseases,
             or seizures

          7. Substance abuse

          8. Severe corn allergy

          9. Known allergic reaction to pentazocine or naloxone

         10. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data

         11. Hysterectomy

         12. Use of anticholinergic medications

         13. Lactating or pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan D Reed, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Susan Reed</investigator_full_name>
    <investigator_title>Professor, Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>hot flashes</keyword>
  <keyword>menopause</keyword>
  <keyword>kappa agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Pentazocine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

